Big Pharma Split (TSX:PRM) Profitability Rank: 0 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:PRM Big Pharma Split Corp TSX:PRM
7 GF Score
Price C$11.61
GF Value C$1.80
View Full Analysis

What is Big Pharma Split Profitability Rank?

Big Pharma Split has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is rated on a scale of 1 to 10 and is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.

Big Pharma Split's Operating Margin % for the quarter that ended in Dec. 2025 was 0.00%. As of today, Big Pharma Split's Piotroski F-Score is 6.

Big Pharma Split Profitability Rank Related Terms

TSX:PRM vs BLK, BX, KKR: Profitability Rank Comparison

For the Asset Management subindustry, Big Pharma Split's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Big Pharma Split Profitability Rank vs Asset Management Industry

For the Asset Management industry and Financial Services sector, Big Pharma Split's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Big Pharma Split's Profitability Rank falls into.


TSX:PRM
7GF Score
Big Pharma Split Corp TSX:PRM
Profitability Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Big Pharma Split Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The rank is rated on a scale of 1 to 10. A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.

Big Pharma Split has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Big Pharma Split's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=0 / 5.483
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Big Pharma Split has an F-score of 6 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank

Is Big Pharma Split (TSX:PRM) Overvalued in 2026?

Based on GuruFocus' analysis, Big Pharma Split stock appears to be overvalued. The current stock price of C$11.61 is trading 545% above its estimated GF Value™ of C$1.80.

Key valuation signals for TSX:PRM:

  • Profitability Rank: 0
  • GF Value™: C$1.80 vs. price of C$11.61 (545% above fair value)
  • GF Score™: 7/100

No single metric tells the full story. See the TSX:PRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Big Pharma Split Business Description

Other Exchanges PRM.PR.A.PFD:Canada
Address 610 Chartwell Road, Suite 204, Oakville, ON, CAN, L6J 4A5
Big Pharma Split Corp is a closed end mutual fund corporation. The investment objective of the company is to provide shareholders with fixed cumulative preferential quarterly cash distributions and regular monthly cash distributions. The company has a presence in the United States, France, and the United Kingdom.
7GF Score

Get the complete analysis for TSX:PRM

Profitability Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$11.61
Price
C$1.80
GF Value